# Cardiotoxicity associated with anticancer therapies for gynecological tumors

## TL;DR

This review discusses how cancer treatments for gynecological tumors can harm the heart and affect long-term health.

## Contribution

The paper systematically reviews cardiovascular risks and mechanisms of various gynecological cancer therapies.

## Key findings

- Chemotherapy, immunotherapy, and other treatments are linked to cardiovascular toxicity.
- Oxidative stress and immune-mediated inflammation are key mechanisms of heart damage.
- Risk factors and strategies for monitoring and managing heart complications are outlined.

## Abstract

The continuous advancement in the management of gynecological cancers has contributed to improved patient survival. Nevertheless, cardiovascular toxicity resulting from anti-tumor treatments has emerged as a significant threat to long-term quality of life and non-cancer-related mortality. This review systematically elaborates on the cardiovascular risk of the conventional treatment of gynecological tumor viz chemotherapy, targeted therapy, immunotherapy, endocrine therapy and radiotherapy. The molecular mechanisms of each therapy will also be discussed, including oxidative stress, mitochondrial dysfunction, endothelial injury and immune-mediated inflammation. Additionally, we outline the major risk factors associated with anticancer therapy related cardiovascular toxicity and give an insight into monitoring, diagnosis and management of complications.